CLNN is approaching a phase 2 trial completion 3x your investment | SEC Filings | NotifyMeEdgar скачать в хорошем качестве

CLNN is approaching a phase 2 trial completion 3x your investment | SEC Filings | NotifyMeEdgar

In this video, I cover why Clene Inc. (CLNN) could be gearing up for a move as it approaches major Phase 2 / Phase 3 clinical trial milestones and a potential FDA approval catalyst. ✅ 8 insiders just filed Form 4s showing stock option grants at $3.60 that vest immediately — a strong bullish signal insiders expect upside soon. ✅ Their latest quarterly report confirms the company was initially denied accelerated approval, but the FDA provided specific guidance on how they can resubmit with new Phase 2 biomarker and survival data. ✅ Management plans to resubmit for FDA review in Q4 2025 using NfL biomarker results collected during ongoing Phase 1 / Phase 2 Expanded Access Programs. ✅ The stock is sitting at multi-year lows and historically these setups have led to explosive moves in small-cap biotech upon positive FDA updates. Tracking insider activity and FDA filings gives you an edge long before the chart moves. 👉 Start getting real-time SEC & FDA catalyst alerts at: https://notifymedgar.com #biotechstocks #BiotechInvesting #FDAApproval #Phase1 #Phase2 #stockmarkettips #ClinicalTrials #InsiderTrading #Form4 #SECfilings #CatalystTrading #SmallCapStocks #MicroCap #SwingTrading #DayTrading #BiotechWatchlist #StocksToWatch #tradingsignals #StockMarketTips #NASDAQStocks #FinTwit #tradingedge #buythedip #medicalbreakthroughs #drugapproval #riskrewardratio #PennyStocks #stockoptions #eventdriventrading #investingstrategy #SmartMoney